Anhui Shi

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Impact of chemotherapy dose reduction during concurrent chemoradiotherapy on survival outcomes in limited-stage small-cell lung cancer.

Impact of chemotherapy dose reduction during concurrent chemoradiotherapy on survival outcomes in limited-stage small-cell lung cancer.

Journal: BMC cancer

Published: April 02, 2026

Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy.

Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy.

Journal: Translational lung cancer research

Published: March 09, 2026

Stratified impact analysis of intrinsic phenotypes and therapeutic interventions on the clinical prognosis of cross-disease validation: right treatment for right patient in precision radiotherapy.

Stratified impact analysis of intrinsic phenotypes and therapeutic interventions on the clinical prognosis of cross-disease validation: right treatment for right patient in precision radiotherapy.

Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Published: January 07, 2026

Nintedanib in the prevention of radiation-induced lung injury in patients with unresectable stage II-III NSCLC: A protocol for a randomized, multicenter, control group study.

Nintedanib in the prevention of radiation-induced lung injury in patients with unresectable stage II-III NSCLC: A protocol for a randomized, multicenter, control group study.

Journal: PloS one

Published: December 16, 2025

Salvage definitive or hypofractionated radiotherapy for oligometastatic recurrence after durvalumab consolidation in limited-stage small-cell lung cancer: a two-case report.

Salvage definitive or hypofractionated radiotherapy for oligometastatic recurrence after durvalumab consolidation in limited-stage small-cell lung cancer: a two-case report.

Journal: Frontiers in oncology

Published: December 13, 2025

Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.

Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 04, 2025

Definitive radiotherapy provides comparable survival with lower toxicity compared with concurrent chemoradiotherapy after long-course induction chemoimmunotherapy in unresectable non-small-cell lung cancer.

Definitive radiotherapy provides comparable survival with lower toxicity compared with concurrent chemoradiotherapy after long-course induction chemoimmunotherapy in unresectable non-small-cell lung cancer.

Journal: Therapeutic advances in medical oncology

Published: November 30, 2025

Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.

Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.

Journal: JTO clinical and research reports

Published: November 07, 2025

Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study.

Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study.

Journal: Targeted oncology

Published: November 07, 2025

Comparative Effectiveness and Safety of PCI versus MRI Surveillance in LS-SCLC.

Comparative Effectiveness and Safety of PCI versus MRI Surveillance in LS-SCLC.

Journal: Practical radiation oncology

Published: October 30, 2025

Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy.

Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy.

Journal: Practical radiation oncology

Published: October 08, 2025

Cumulative Incidence and Type-Specific Risk Factors of Pneumonitis After Definitive Chemoradiotherapy With or Without Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.

Cumulative Incidence and Type-Specific Risk Factors of Pneumonitis After Definitive Chemoradiotherapy With or Without Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.

Journal: Clinical lung cancer

Published: July 18, 2025

Showing 1-12 of 50

Last Updated: 09/26/2026